CNS Pharmaceuticals (CNSP) stock was trading up 215.39% on Monday, at around $2.31, after the biotech company announced it had closed agreements for a private placement that exceeded investor demand.
CNS Pharmaceuticals, Inc., CNSP
The offering aims to raise approximately $22.5 million in gross proceeds. That’s a large sum relative to the company’s market cap, which stood at just $1.88 million before the announcement.
The deal structure includes 650,000 shares of common stock priced at $2.30 each. It also includes pre-funded warrants for an additional 9,143,479 shares priced at $2.299, with an exercise price of just $0.001 per share.
The offering is expected to close on Tuesday.
Institutional healthcare investors drove the oversubscription. Participants include ADAR1 Capital, Ikarian Capital, Stonepine Capital Management, and Nazare Partners — all names with established presence in the biotech space.
CEO Rami Levin said the company is now positioned to “execute on our recently announced corporate strategy.” He pointed to plans to acquire assets with “clear development pathways” and “identifiable near-term catalysts.”
Trading activity on Monday was remarkable by CNSP’s standards. More than 44 million shares changed hands — against a three-month daily average of just 16,000. That’s a volume surge of roughly 2,750 times the norm.
The stock was already up 89.52% year-to-date heading into Monday. Even with today’s explosion higher, CNSP remains down 82.49% over the trailing 12 months, reflecting how beaten-down this stock had become.
The 52-week high sits at $34.80. Monday’s price near $2.31 shows just how far the stock had fallen before this catalyst hit.
CNS Pharmaceuticals is focused on treatments for serious diseases, with particular attention to glioblastoma multiforme — a severe form of brain cancer.
The company’s strategy has been shifting. It is exploring out-licensing opportunities for two legacy assets: TPI 287 and Berubicin. New capital gives it room to pursue acquisitions with near-term development milestones.
GuruFocus data paints a cautious picture of the company’s fundamentals. CNSP holds a GF Score of 32 out of 100, a Piotroski F-Score of 3, and a profitability rank of just 1 out of 10. The company has no P/E ratio due to negative earnings — standard for development-stage biotechs.
Financial strength is rated at 7 out of 10, suggesting the balance sheet has some stability even as operations remain unprofitable.
Only one Wall Street analyst currently covers the stock. Maxim Group’s Jason McCarthy holds a Buy rating with a $10 price target on CNSP — implying around 5.6% upside from current levels following Monday’s surge.
No insider buying or selling has been reported in the past 12 months.
The post Why CNS Pharmaceuticals (CNSP) Stock Is Up 215% Today appeared first on CoinCentral.
